• GDC-0068: A Signal-Deconvolution Tool

  2026-09-10

  GDC-0068 (RG7440) is a selective pan-AKT inhibitor for dissecting PI3K/Akt/mTOR signaling, genotype-dependent vulnerability, and treatment-induced feedback. This article presents an assay-centered framework that connects Akt perturbation with spatially resolved mTORC1 biology.

• SAR405: Reliable Vps34 Inhibition in Cell Assays

  2026-09-10

  This scenario-based guide explains how SAR405 (SKU A8883) can clarify autophagy, vesicle-trafficking, and lysosomal phenotypes that are often obscured in cell viability assays. It covers experimental design, reagent handling, interpretation, and practical criteria for selecting a well-characterized Vps34 inhibitor.

• Pseudo-UTP for mRNA Synthesis Workflows

  2026-09-09

  Pseudo-UTP enables controlled pseudouridine incorporation during in vitro transcription, supporting RNA stability enhancement, translation studies, and innate-immune profiling. This practical guide covers substitution design, assay controls, optimization, and the limitations that matter for mRNA vaccine development and gene therapy RNA modification.

• Melittin in GPCR and Glioblastoma Research

  2026-09-09

  Melittin is a bioactive peptide for dissecting Gs/Gi-dependent signaling, migration, apoptosis, and lipid-linked mechanisms in glioblastoma models. This guide converts the miR-18a/ALOXE3 findings into a controlled workflow that separates acute signal transduction from cytotoxicity and ferroptosis-related effects.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-08

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator in colorectal cancer. By linking NAT1-dependent ENO1 acetylation to lactate-driven TRAF6 activation and PD-L1 stabilization, the work provides a mechanistic explanation for how tumor metabolism can shape immune checkpoint responses.

• Grazoprevir/Elbasvir: Evidence from HCV Therapy

  2026-09-07

  The reference review explains how complementary NS3/4A protease and NS5A inhibition established grazoprevir/elbasvir as an interferon-free strategy for chronic HCV infection. Its practical significance lies in consistently high virologic response, applicability to difficult-to-treat populations, and a framework for evaluating resistance, treatment duration, and drug interactions.

• Silk Fibroin–Ce6 Films for Infected Wound Healing

  2026-09-07

  The reference study develops an aligned silk fibroin electrospun film conjugated with Chlorin e6 (Ce6) for near-infrared photodynamic treatment of Staphylococcus aureus-infected wounds. Its importance lies in combining rapid reactive oxygen species generation with anisotropic cell-guidance properties and later-stage macrophage M2 polarization, linking infection control with tissue repair.

• Amikacin (BAY416651): From Mechanism to Translation

  2026-09-05

  A translational perspective on Amikacin (BAY416651), connecting 30S ribosome engagement, resistance-mechanism studies, and targeted delivery into mycobacterial granulomas.

• BRD4 Inhibition Amplifies Erastin-Induced Ferroptosis

  2026-09-05

  The reference study identifies BRD4 inhibition as a broadly active sensitizer of erastin-induced ferroptosis across several cellular models. Its data connect increased reactive oxygen species with reduced FSP1 expression, providing a mechanistic rationale for combining BET inhibition with ferroptosis-based strategies in cancer biology research.

• Proteinase K for Fungal EV Assay Design

  2026-09-04

  Proteinase K is more than a routine DNA extraction reagent: it can help researchers design cleaner, more interpretable fungal extracellular-vesicle assays. This article connects its proteolytic mechanism and matrix tolerance with a recent Candida albicans study while clearly separating established evidence from workflow recommendations.

• GDC-0068 (RG7440) Pan-AKT Inhibitor

  2026-09-04

  GDC-0068, also called RG7440, is an ATP-competitive pan-AKT inhibitor with activity against Akt1, Akt2, and Akt3. Product data support its use for studying PI3K/Akt/mTOR signaling, tumor-cell proliferation, cell-cycle control, and tumor models with PTEN loss or PI3K alterations.

• PF-04971729 Workflow for SGLT2 Research

  2026-09-03

  Ertugliflozin (PF-04971729) supports more than a standard glucose-uptake assay: it can connect SGLT2-mediated transport, metabolic phenotyping, cardiovascular endpoints, and exploratory mucosal-repair models. This practical guide covers dosing design, solvent control, translational assay selection, and troubleshooting for diabetes mellitus research.

• Axitinib Workflows for VEGF Signaling Assays

  2026-09-02

  Build more informative angiogenesis and cancer biology experiments with Axitinib (AG 013736), from receptor-proximal phospho-signaling assays to viability and xenograft study design. The workflow separates growth suppression from true cell killing while addressing solubility, timing, controls, and translational limits.

• sEV CD147 Drives HCC Angiogenesis via PI3K/Akt

  2026-09-02

  Huang et al. identified CD147-positive small extracellular vesicles as both a circulating HCC-associated signal and a functional mediator of endothelial angiogenesis. Their integrated clinical, cellular, and Matrigel plug experiments connect vesicle-associated CD147 with VEGFA induction through PI3K/Akt, providing a mechanistic framework for biomarker development and pathway validation.

• Foretinib (GSK1363089) Cancer Assay Workflows

  2026-09-02

  Build more informative Foretinib response studies by separating growth arrest from cell death and pairing viability with motility, invasion, and metastasis readouts. This workflow uses the compound’s Met–VEGFR activity to connect mechanistic cell assays with ovarian cancer xenograft and other translational models.

8242 records 1/550 page Next 12345 下5页 Last page